金迪克(688670.SH)2025年度归母净亏损1.73亿元

Core Viewpoint - The company reported a significant increase in revenue for the fiscal year 2025, but also experienced a substantial net loss attributed to increased R&D expenses and asset impairment provisions [1] Financial Performance - The company's revenue for 2025 reached 113 million, representing a year-on-year growth of 40.13% [1] - The net loss attributable to the parent company was 173 million, compared to a loss of 93.5 million in the same period last year [1] Operational Highlights - The revenue growth was driven by proactive production scheduling, improved departmental coordination, and enhanced production efficiency, particularly in flu vaccine production and approval processes [1] - The company focused on deepening customer service, optimizing marketing management systems, and expanding into new markets to increase product coverage [1] Profitability Metrics - Various profitability metrics, including operating profit, total profit, and net profit attributable to the parent company, showed significant fluctuations during the reporting period [1] - The changes in these metrics were primarily influenced by substantial increases in R&D investment, provisions for asset impairment, and inventory write-offs [1]